Clinical Trials
7 trialsNCT06385483 2026-05-28
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02438722 2026-05-18
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
SWOG Cancer Research Network
Phase 2/3 Completed
NCT04439136 2026-04-29
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02979977 2026-02-04
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Yale University
Phase 2 Completed
NCT01856478 2026-01-12
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed
NCT00716417 2025-08-05
Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT02191891 2025-06-25
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim
Phase 1 Completed